Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • New Meta-Analysis Questions Routine Vitamin D Supplementation During Pregnancy to Prevent Preterm Birth
    16 July 2026

    New Meta-Analysis Questions Routine Vitamin D Supplementation During Pregnancy to Prevent Preterm Birth

    A comprehensive systematic review and meta-analysis published in the journal BIO Integration has found that routine vitamin D supplementation during pregnancy does not provide convincing evidence for preventing preterm birth. The analysis also highlighted that an apparent increase in preterm birth risk observed in one subgroup should be interpreted with caution because it was driven by a single clinical trial involving women living with HIV, rather than the broader pregnant population.

  • Gujarat State Pharmacy Council and IPC Launch Dedicated Pharmacovigilance & Medicine Safety Portal
    16 July 2026
    Gujarat State Pharmacy Council and IPC Launch Dedicated Pharmacovigilance & Medicine Safety Portal

    The Gujarat State Pharmacy Council (GSPC) has partnered with the Indian Pharmacopoeia Commission (IPC) to launch a dedicated "Pharmacovigilance & Medicine Safety" to strengthen medicine safety awareness and promote adverse drug reaction (ADR) reporting

  • European Commission Approves Novo Nordisk's Oral Wegovy, Marking New Era in Obesity Treatment
    16 July 2026
    European Commission Approves Novo Nordisk's Oral Wegovy, Marking New Era in Obesity Treatment

    Novo Nordisk has announced that the European Commission (EC) has approved Wegovy® (semaglutide) tablets for chronic weight management, making it the first oral GLP-1 receptor agonist authorized in the European Union for the treatment of obesity and overweight. The approval also includes a single, ready-to-use 7.2 mg Wegovy injection pen, providing healthcare professionals and patients with additional treatment options.

  • Sanofi Files Patent Lawsuit Against Moderna Over mRNA Vaccine Technology
    16 July 2026
    Sanofi Files Patent Lawsuit Against Moderna Over mRNA Vaccine Technology

    Sanofi has filed a patent infringement lawsuit against Moderna in the U.S. District Court for the District of New Jersey, alleging that Moderna's mRNA vaccine technologies infringe a portfolio of patents originally developed by Translate Bio, a biotechnology company acquired by Sanofi in 2021. The complaint names Translate Bio, Translate Bio MA, Sanofi Vaccines US, and VaxServe as plaintiffs, while Moderna, ModernaTX, and Moderna US are listed as defendants.

  • FDA Approves First Generic Afatinib Tablets for Lung Cancer; Apotex and Hetero Secure U.S. Approval
    15 July 2026
    FDA Approves First Generic Afatinib Tablets for Lung Cancer; Apotex and Hetero Secure U.S. Approval
    The U.S. Food and Drug Administration (FDA) has approved the first generic versions of GILOTRIF (afatinib) tablets, marking an important milestone in expanding access to targeted therapy for patients with specific forms of non-small cell lung cancer (NSCLC). The approval covers generic afatinib tablets manufactured by Apotex Inc. and Hetero Labs Limited Unit V.
  • FDA Flags Medtronic Pulmonary Valve Delivery System Recall as Class I Over Risk of Catheter Tip Detachment
    14 July 2026
    FDA Flags Medtronic Pulmonary Valve Delivery System Recall as Class I Over Risk of Catheter Tip Detachment

    The U.S. Food and Drug Administration (FDA) has announced a Class I recall, its most serious recall category, for certain Medtronic Harmony™ Delivery Catheter Systems (DCS) used to implant transcatheter pulmonary valves. The recall follows concerns that a manufacturing defect could cause the catheter's distal tip to detach during implantation, potentially leading to serious complications, including emergency surgery or death.

  • FDA Approves First At-Home Starting Dose for Alzheimer's Therapy, Expanding Access to Early Treatment
    14 July 2026
    FDA Approves First At-Home Starting Dose for Alzheimer's Therapy, Expanding Access to Early Treatment

    The U.S. Food and Drug Administration (FDA) has approved the first at-home starting dose for an Alzheimer's disease treatment, marking a significant advancement in the management of early Alzheimer's disease. The approval allows eligible patients to begin therapy using a subcutaneous (under-the-skin) injection at home, either by self-administration or with the assistance of a caregiver, reducing the need for hospital or infusion-center visits.

  • IPA Seeks High-Level Probe into Delhi Pharmacy Council, Cites Governance Concerns and Registration Delays
    14 July 2026
    IPA Seeks High-Level Probe into Delhi Pharmacy Council, Cites Governance Concerns and Registration Delays

    The Indian Pharmacist Association (IPA) has written to the Lieutenant Governor of Delhi seeking a high-level independent inquiry into the functioning of the Delhi Pharmacy Council (DPC). In a letter dated 12 July 2026, the association requested immediate intervention, alleging that administrative shortcomings and prolonged registration delays are adversely affecting pharmacy students and registered pharmacists.

  • Scientists Discover Hepatitis E Virus Begins Evolving Within Weeks of Infection
    13 July 2026
    Scientists Discover Hepatitis E Virus Begins Evolving Within Weeks of Infection

    Researchers from Ruhr University Bochum, Germany, have uncovered new evidence showing that the hepatitis E virus (HEV) begins evolving much earlier during infection than previously understood. The findings, published in the journal mBio, reveal that although the virus exhibits relatively low genetic diversity during the acute phase, it rapidly acquires specific recurring mutations within just a few weeks of infection. The discovery offers new insights into how HEV adapts inside the human body and could help guide future antiviral research.

  • Emcure Takes Full Control of Gennova, Bets Big on Biologics and Biosimilars Under New Leadership
    13 July 2026
    Emcure Takes Full Control of Gennova, Bets Big on Biologics and Biosimilars Under New Leadership

    Emcure Pharmaceuticals Limited has announced a major strategic restructuring of its biopharmaceutical business by acquiring the remaining 12.05% minority stake in Gennova Biopharmaceuticals Limited, making it a wholly owned subsidiary. The company also announced a leadership transition, appointing Samit Mehta to lead Gennova as it sharpens its focus on biologics, biosimilars, and next-generation therapeutic platforms.

Subscribe to Pharma News